메타지노미 테라퓨틱스MGX 주가

Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $12 to $9.

Metagenomi Q1 EPS $(0.61) Misses $(0.55) Estimate, Sales $1.248M Miss $5.925M Estimate

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 10.29 percent increase over losses of $(0.68) per share from the

Metagenomi Therapeutics: Q1 Earnings Snapshot

EMERYVILLE, Calif. — EMERYVILLE, Calif. — Metagenomi Therapeutics, Inc. on Monday reported a loss of $23.1 million in its first quarter. The Emeryville, California-based company said it had a...

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application in 4Q 2026 Publication in Nature Structural & Molecular Biology...

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K

[ARS] ARS — ARS

[DEFA14A] DEFA14A — DEFA14A

[DEF 14A] 주주총회 위임장 — DEF 14A

[4] 내부자 거래 — 4